Clinical and Epidemiologic Features of Cryptosporidium-Associated Diarrheal Disease Among Young Children Living in Sub-Saharan Africa: The Vaccine Impact on Diarrhea in Africa (VIDA) Study.
Cryptosporidium
children
diarrhea
prevalence
severity
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
19 04 2023
19 04 2023
Historique:
medline:
21
4
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
As part of the Vaccine Impact on Diarrhea in Africa (VIDA) Study, we examined the prevalence, clinical presentation, and seasonality of Cryptosporidium in children to understand its relative burden after the introduction of rotavirus vaccine. VIDA was a 3-year, age-stratified, matched case-control study of medically attended acute moderate-to-severe diarrhea (MSD) in children aged 0-59 months residing in censused populations at sites in Kenya, Mali, and The Gambia. Clinical and epidemiologic data were collected at enrollment, and a stool sample was tested for enteropathogens by quantitative PCR. An algorithm was created based on the organism's cycle threshold (Ct) and association with MSD to identify the subset of Cryptosporidium PCR-positive (Ct <35) cases most likely to be attributed to MSD. Clinical outcomes were assessed at 2-3 months after enrollment. One thousand one hundred six (22.9%) cases of MSD and 873 controls (18.1%) were PCR positive for Cryptosporidium; 465 cases (42.0%) were considered attributable to Cryptosporidium, mostly among children 6-23 months. Cryptosporidium infections peaked in The Gambia and Mali during the rainy season, while in Kenya they did not have clear seasonality. Compared with cases with watery MSD who had a negative PCR for Cryptosporidium, cases with watery MSD attributed to Cryptosporidium were less frequently dehydrated but appeared more severely ill using a modified Vesikari scale (38.1% vs 27.0%; P < 0.001), likely due to higher rates of hospitalization and intravenous fluid administration, higher prevalence of being wasted or very thin very thin (23.4% vs 14.7%; P < 0.001), and having severe acute malnutrition (midupper arm circumference <115 mm, 7.7% vs 2.5%; P < 0.001). On follow-up, Cryptosporidium-attributed cases had more prolonged and persistent episodes (43.2% vs 32.7%; P <0 .001) and linear growth faltering (change in height-for-age z score between enrollment and follow-up: -0.29 vs -0.17; P < 0.001). The burden of Cryptosporidium remains high among young children in sub-Saharan Africa. Its propensity to cause illness and further impact children longer term by compromising nutritional status early in life calls for special attention to enable appropriate management of clinical and nutritional consequences.
Sections du résumé
BACKGROUND
As part of the Vaccine Impact on Diarrhea in Africa (VIDA) Study, we examined the prevalence, clinical presentation, and seasonality of Cryptosporidium in children to understand its relative burden after the introduction of rotavirus vaccine.
METHODS
VIDA was a 3-year, age-stratified, matched case-control study of medically attended acute moderate-to-severe diarrhea (MSD) in children aged 0-59 months residing in censused populations at sites in Kenya, Mali, and The Gambia. Clinical and epidemiologic data were collected at enrollment, and a stool sample was tested for enteropathogens by quantitative PCR. An algorithm was created based on the organism's cycle threshold (Ct) and association with MSD to identify the subset of Cryptosporidium PCR-positive (Ct <35) cases most likely to be attributed to MSD. Clinical outcomes were assessed at 2-3 months after enrollment.
RESULTS
One thousand one hundred six (22.9%) cases of MSD and 873 controls (18.1%) were PCR positive for Cryptosporidium; 465 cases (42.0%) were considered attributable to Cryptosporidium, mostly among children 6-23 months. Cryptosporidium infections peaked in The Gambia and Mali during the rainy season, while in Kenya they did not have clear seasonality. Compared with cases with watery MSD who had a negative PCR for Cryptosporidium, cases with watery MSD attributed to Cryptosporidium were less frequently dehydrated but appeared more severely ill using a modified Vesikari scale (38.1% vs 27.0%; P < 0.001), likely due to higher rates of hospitalization and intravenous fluid administration, higher prevalence of being wasted or very thin very thin (23.4% vs 14.7%; P < 0.001), and having severe acute malnutrition (midupper arm circumference <115 mm, 7.7% vs 2.5%; P < 0.001). On follow-up, Cryptosporidium-attributed cases had more prolonged and persistent episodes (43.2% vs 32.7%; P <0 .001) and linear growth faltering (change in height-for-age z score between enrollment and follow-up: -0.29 vs -0.17; P < 0.001).
CONCLUSIONS
The burden of Cryptosporidium remains high among young children in sub-Saharan Africa. Its propensity to cause illness and further impact children longer term by compromising nutritional status early in life calls for special attention to enable appropriate management of clinical and nutritional consequences.
Identifiants
pubmed: 37074443
pii: 7130324
doi: 10.1093/cid/ciad044
pmc: PMC10116562
doi:
Substances chimiques
Rotavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S97-S105Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest . E. R. H. reports financial support from the Bill and Melinda Gates Foundation (OPP1129479). K. L. K. reports consultation fees and travel support from PATH and the University of Washington related to diarrheal diseases and grant support to her institution from the National Institutes of Health, Institut Pasteur, and the Bill & Melinda Gates Foundation. S. M. T. reports multiple grants paid to her institution from the National Institutes of Health (NIH), Bill & Melinda Gates Foundation (BMGF), Wellcome Trust, Affinivax, Lumen Biosciences, PATH, and Medical Research Council. She also reports payments as royalties related to intellectual property for Salmonella vaccines and Klebsiella/Pseudomonas vaccines and consulting fees and travel support from the University of Washington for a grant proposal. She also reports holding multiple planned, issued, and pending patents on Salmonella, Klebsiella, and Pseudomonas vaccines and hold multiple unpaid committee roles with the American Society of Tropical Medicine and Hygiene. S. R. C. H. reports salary funding from the UK Medical Research Council and the University of Auckland. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
J Trop Med Hyg. 1994 Apr;97(2):103-7
pubmed: 8169999
BMJ. 1993 Aug 14;307(6901):417-20
pubmed: 8374453
PLoS Negl Trop Dis. 2021 Mar 11;15(3):e0009057
pubmed: 33705395
Lancet. 2002 Nov 2;360(9343):1375-80
pubmed: 12423984
Wkly Epidemiol Rec. 2009 Dec 18;84(50):533-40
pubmed: 20034143
PLoS Negl Trop Dis. 2015 Mar 06;9(3):e0003551
pubmed: 25749411
Lancet Infect Dis. 2021 May;21(5):722-730
pubmed: 33278916
Am J Trop Med Hyg. 1999 Nov;61(5):707-13
pubmed: 10586898
Lancet Glob Health. 2020 Feb;8(2):e204-e214
pubmed: 31864916
PLoS Negl Trop Dis. 2018 Jul 12;12(7):e0006640
pubmed: 30001340
Am J Trop Med Hyg. 2009 May;80(5):824-6
pubmed: 19407131
Lancet Infect Dis. 2018 Nov;18(11):1211-1228
pubmed: 30243583
Am J Trop Med Hyg. 2002 Jun;66(6):787-93
pubmed: 12224593
PLoS Pathog. 2021 Jun 28;17(6):e1009445
pubmed: 34181697
Am J Trop Med Hyg. 1999 Jan;60(1):157-64
pubmed: 9988341
PLoS Negl Trop Dis. 2014 Mar 27;8(3):e2758
pubmed: 24675990
Clin Infect Dis. 2017 Feb 1;64(3):347-354
pubmed: 28013266
Am J Clin Nutr. 1997 Jan;65(1):149-52
pubmed: 8988927
Lancet Infect Dis. 2015 Jan;15(1):85-94
pubmed: 25278220
J Water Health. 2009 Mar;7(1):67-75
pubmed: 18957776
Matern Child Nutr. 2016 May;12 Suppl 1:12-26
pubmed: 27187907
Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45
pubmed: 23169936
Am J Trop Med Hyg. 2004 Jan;70(1):83-8
pubmed: 14971703
J Infect Dis. 1999 Jul;180(1):167-75
pubmed: 10353875
Curr Opin Infect Dis. 2021 Oct 1;34(5):455-462
pubmed: 34261904
PLoS Negl Trop Dis. 2016 May 04;10(5):e0004564
pubmed: 27144404
Int J Epidemiol. 2022 Oct 13;51(5):1469-1480
pubmed: 35578827
Clin Infect Dis. 2023 Apr 19;76(Supplement_1):S5-S11
pubmed: 37074428
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Curr Opin Infect Dis. 2012 Oct;25(5):555-63
pubmed: 22907279
Nature. 2019 Oct;574(7778):353-358
pubmed: 31619795
Lancet Glob Health. 2018 Jul;6(7):e758-e768
pubmed: 29903377
Ann Trop Paediatr. 2001 Dec;21(4):313-8
pubmed: 11732149
J Infect Dis. 2020 Oct 13;222(10):1731-1739
pubmed: 32095831
J Biomol Struct Dyn. 2022 May 5;:1-18
pubmed: 35510602
Food Waterborne Parasitol. 2021 Aug 20;24:e00131
pubmed: 34471706
Trans R Soc Trop Med Hyg. 2022 Mar 2;116(3):270-277
pubmed: 34388242
Ann Trop Med Parasitol. 2008 Jun;102(4):309-15
pubmed: 18510811
Expert Rev Vaccines. 2017 Oct;16(10):987-995
pubmed: 28832219
Am J Epidemiol. 1998 Sep 1;148(5):497-506
pubmed: 9737562
J Infect Dis. 2021 Dec 20;224(12 Suppl 2):S848-S855
pubmed: 34528677
PLoS Negl Trop Dis. 2019 Jul 26;13(7):e0007607
pubmed: 31348795